Search the Knowledge Hub Archive
PMS, PMCF and lifecycle evidence: Key takeaways from the TT Lifesciences PMSV & QARA Conference
Key takeaways from the TT Lifesciences PMSV & QARA Conference, exploring the connection between PMS and PMCF, the importance of meaningful lifecycle evidence, and how well-designed surveys can help close evidence gaps
The End of Buying the Box
As MedTech commercial models evolve beyond traditional equipment sales, customers are increasingly evaluating long-term partnerships rather than standalone products. This article explores how subscriptions, managed services and outcome-focused agreements are reshaping buying decisions and what suppliers must do to deliver value throughout the customer relationship.
RAPS Convergence 2026: Navigating Regulatory Change, Real-World Evidence and AI in MedTech
Our key takeaways from RAPS Convergence 2026 highlight the growing importance of PMCF, real-world evidence and robust study design in an evolving MedTech regulatory landscape
From Data to Decisions: Research, Technology and Partnership in Practice
How can research teams move more efficiently from data collection to actionable insights? In this co-authored article, Purdie Pascoe and Displayr explore how research expertise, technology and collaboration can streamline analysis, accelerate reporting and make insights more accessible through interactive dashboards and data visualisation.
How better planning helps insights resonate further across the business
Great research is only valuable if it drives action. Discover how better planning, stakeholder engagement and tailored deliverables can help insights resonate further across the business.
From Curiosity to Confidence: Using AI Thoughtfully in MedTech Market Research
Artificial intelligence is becoming an increasingly practical part of market research. From desk research and proposal development to qualitative analysis, reporting and data visualisation, AI is already helping teams manage information more efficiently and explore ideas in new ways. But the real opportunity is not simply to do the same work faster. The more important question is: how can AI help researchers ask better questions, strengthen their thinking and deliver more meaningful insight for clients?
What EBME Expo 2026 Revealed About the Future of Healthcare Technology
Recently, Director Hazel Haskayne and Director Sebastian Newton attended the EBME Expo, one of the UK's leading events for healthcare technology and medical equipment professionals.
While much of the conference focused on clinical engineering, several themes emerged that highlight how healthcare technology, procurement and innovation are continuing to evolve across the NHS and wider healthcare sector.
Cracking complex MedTech decisions
SIMALTO is designed to reveal what stakeholders value most when they have to balance real-world demands alongside cost. Rather than rating each feature in isolation, respondents are asked to make choices, showing what they are prepared to prioritise and what they are willing to give up.
Endpoints: The foundation of meaningful evidence in medical device research
We recently ran an internal knowledge-sharing session on endpoints, something we address every day in our post market survey work. We took a step back to define their critical role in protocol and survey design, and how these feed into medical device evaluations and regulations.
Partnership with Metaforms: Supporting smarter survey programming
At Purdie Pascoe, the best partnerships are the ones that make a real difference to how we work day-to-day, and Metaforms is a strong example of that. It is an AI-assisted platform that supports survey programming, helping turn complex questionnaires into live surveys with less manual effort. One project type that used to take about a week of programming now takes two to three days. For our team, that creates more space to respond when clients need updates with a quick turnaround.
What’s really shaping MedTech in 2026? A mid-year round-up of insights
As we reach the midpoint of 2026, a clear picture is emerging from the conversations we've been having across the MedTech industry. While the topics may seem different on the surface, many are converging around a broader shift in how organisations think about evidence, insight, and the journey from innovation to real-world adoption. Rather than a set of trends or predictions, these are recurring themes we're seeing in practice and believe will continue to shape decision-making across the industry.
Why MedTech companies are rethinking the ‘house of brands’ model
Many MedTech companies are rethinking the house of brands model as portfolios become more complex through platforms, digital ecosystems, and long-term partnerships. A stronger masterbrand can help scale trust across the portfolio, simplify complexity, and support adoption of new technologies and services.
PMCF expertise published in Journal of Medical Device Regulation 2026
This article explores the role of post-market RWD/RWE in establishing sufficient clinical evidence for legacy devices transitioning to the MDR. It outlines key data sources, explains how off-label data can be captured and used, shares Notified Body perspectives and case study examples, and considers how post-market surveys can generate high-quality RWD. It concludes with practical guidance on integrating these data into an ongoing clinical evidence strategy.
Data, Data, Data: Why innovation is the quiet force behind great research
Behind every great research project is a system quietly keeping thousands of data points accurate, scalable, and insight ready. In this article, our Programming & Analytics experts explore how automation and innovation are transforming large-scale market research, freeing researchers to focus on what matters most: delivering meaningful insight.
Why qualitative research matters in MedTech (and why it’s often undervalued)
Behavioural economics has long highlighted the importance of context. Data without context will only get you so far. MedTech companies need to understand why clinicians behave the way they do, how decisions actually get made inside hospitals, what ‘risk’ really means to different stakeholders and where friction exists within workflows, perceptions and emotions.
Smarter workflows, sharper insights: How our dedicated Innovation team helps us (and our clients) work better
Innovation sits right at the intersection of data, technology, and research. Our Innovation team’s goal is simple: make complex studies easier to run, insights easier to find, and decisions easier to make, for both our research colleagues and our clients.
Real-World Data: The fuel behind modern clinical evidence, and why Post Market Surveys are a smart way to capture it
As regulators worldwide including the FDA and EU Notified Bodies place greater emphasis on RWD, the industry faces a familiar but intensified challenge: how to generate high-quality, device-specific evidence efficiently, reliably, and without escalating costs. That’s where Post-Market Surveys come in.
Are Multi Cancer Early Detection Tests (MCEDs) the new frontier in proactive healthcare for consumers?
Imagine a simple blood test that could screen for dozens of cancers, long before symptoms appear. This is the promise of Multi-Cancer Early Detection (MCED), a rapidly emerging field that has the potential to transform how we approach cancer screening globally. As with any breakthrough, the success of MCED will depend not only on the science, but also on public awareness, understanding and interest, healthcare system readiness, and equitable access.
Gender bias in medical device research: Why disaggregated data matters
By analysing data through a more granular lens, including disaggregation by gender, we can uncover meaningful insights, identify differential responses, and ultimately drive more equitable outcomes for all patient groups. Doing so also supports alignment with regulatory expectations around inclusive and evidence based post-market surveillance.
The MedTech Difference: Insights from Industry Leaders
Sabera Hyderally, Purdie Pascoe’s Head of US MedTech, recently facilitated an engaging, honest, and thought-provoking conversation with experts from across the MedTech and Diagnostics industry. The discussion explored how MedTech differs from other sectors, particularly pharmaceuticals, and what these differences mean for how we approach market research, innovation, and patient engagement.